Narayana Hrudayalaya Ltd (NH) is currently trading at 1,929.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Narayana Health operates a multi-specialty and super-specialty healthcare network across India, the Cayman Islands and the United Kingdom, combining owned hospitals, managed facilities, clinics, dialysis centres and insurance operations. As of October 2026, the group had 56 healthcare facilities, 6,119 operational beds, 6,374 total capacity beds and approximately 21,150 employees. The group delivered consolidated Q2 FY27 operating revenue of ₹28,440 million, up 73.0% year-on-year, while EBITDA rose 42.0% to ₹6,054 million. However, reported growth includes the United Kingdom business acquired in FY26, making India and Cayman operating trends more useful indicators of underlying performance. India remains the earnings engine, with Q2 revenue growth of 16.7% year-on-year and EBITDA margin improving to 26.8%. Patient activity also strengthened, with hospital outpatient footfalls rising to 744,000 and inpatient discharges reaching 60,000, while average length of stay remained stable at 4.3 days. Narayana Health is pursuing a sizeable capacity build-out toward 7,800-plus beds by FY30, supported by projects in Bengaluru, Kolkata and Raipur. The expansion should improve regional density and long-term revenue potential, but execution, funding requirements and ramp-up losses will determine whether new capacity translates into sustained returns. International operations are mixed: Cayman delivered strong revenue and EBITDA growth, whereas the United Kingdom experienced sequential revenue decline and margin compression. The nascent insurance business also reported a ₹151 million loss with a 282% combined operating ratio, highlighting meaningful volatility outside core hospitals.

Over the past 52 weeks, Narayana Hrudayalaya Ltd has traded between a low of ₹1,564.25 and a high of ₹2,094.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Narayana Hrudayalaya Ltd has a market capitalization of approximately 38,205.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Narayana Hrudayalaya Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 44.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 38,205.25 Cr, Narayana Hrudayalaya Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Narayana Hrudayalaya Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Narayana Hrudayalaya Ltd is 44.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

NH targets more than 7,800 beds by FY30, from stated capacity of 5,879 beds on 30 September 2026. Its identified additions include 1,555 beds across six named projects and a further 400-bed pipeline.

NH India Hospitals reported an EBITDA margin of 26.8% in Q2 FY27. This was 3.0 percentage points above 23.8% in Q2 FY26 and 2.0 percentage points above 24.8% in Q1 FY27. EBITDA was Rs 37.99 crore for the quarter.

HCCI EBITDA increased 46.4% quarter on quarter to US$22.1 million in Q2 FY27 from US$15.1 million in Q1 FY27. It was also 23.8% above US$17.9 million in Q2 FY26. HCCI profit after tax rose to US$16.6 million from US$10.2 million sequentially.

NH is targeting more than 7,800 beds by FY30. It reported 5,879 beds on 30 September 2026 and identified 1,555 beds in six projects plus 400 beds in pipeline.